Tipiracil

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Retrieved on: 
星期六, 四月 10, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Organic compounds, Chemical compounds, Chemistry, Chloroarenes, Pyridines, Regorafenib, Ureas, Tipiracil, Progression-free survival, Cancer, Etrumadenant, Arcus Biosciences

Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)

Key Points: 
  • Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)
    Median progression-free survival (PFS) of 4.2 months.
  • Reported data for current standard-of-care (SOC) therapies have shown a median PFS of 2.0 and 1.9 months for trifluridine-tipiracil and regorafenib, respectively3,4.
  • Reported data for trifluridine-tipiracil and regorafenib have shown a median OS of 7.1 and 6.4 months, respectively3,4.
  • Few options exist today to treat third-line colorectal cancer, and these therapies are associated with significant toxicity and limited efficacy.

NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens with Alternative Mechanism of Action

Retrieved on: 
星期六, 一月 25, 2020
Software, Practice Management, Internet, Oncology, Health, Data management, Hospitals, Technology, Life sciences, Articles, Health, Antineoplastic drugs, Cancer treatments, Chloroarenes, Pyridines, Regorafenib, Ureas, Tipiracil, Oncology, Biopharmaceutical

NantHealths presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealths Eviti Connect , an evidence-based treatment intelligence and web-based oncology decision support platform.

Key Points: 
  • NantHealths presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealths Eviti Connect , an evidence-based treatment intelligence and web-based oncology decision support platform.
  • Detailed information from 6,325 treatment plans was analyzed to identify treatment patterns using regorafenib and trifluridine + tipiracil for advanced CRC patients as third-line of therapy.
  • National Comprehensive Cancer Network (NCCN) guidelines state that regorafenib and trifluridine+tipiracil are both treatment options for patients who have progressed through all available regimens.
  • Our analysis shows that recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action, said William A.

Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium

Retrieved on: 
星期五, 九月 28, 2018
Chemistry, Medicine, Health, Chloroarenes, Pyridines, Regorafenib, Ureas, Antineoplastic drugs, Combination drugs, Taiho Pharmaceutical, Trifluridine/tipiracil, Tipiracil

PRINCETON, N.J., Sept. 28, 2018 /PRNewswire/ --Taiho Oncology, Inc. today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF(trifluridine and tipiracil) or Stivarga(regorafenib).

Key Points: 
  • PRINCETON, N.J., Sept. 28, 2018 /PRNewswire/ --Taiho Oncology, Inc. today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF(trifluridine and tipiracil) or Stivarga(regorafenib).
  • * In this retrospective study, medication adherence was assessed among adult patients with mCRC receiving LONSURF (469) or regorafenib (311).
  • Additionally, patients receiving LONSURF before regorafenib remained on treatment longer than those receiving regorafenib followed by LONSURF.
  • In Japan, Taiho Pharmaceutical has been marketing LONSURF for the treatment of metastatic advanced or recurrent colorectal cancer since 2014.